Already a member? Sign in
Imipramine is a tricyclic antidepressant used for the treatment of depression; treatment of nocturnal enuresis in children. Off label it is used as an analgesic for certain chronic and neuropathic pain; panic disorder; and attention-deficit/hyperactivity disorder (ADHD).
| Purpose | # of patients |
# of patients with evaluations
Efficacy
|
Major | Moderate | Slight | None | Can’t tell |
|---|---|---|---|---|---|---|---|
| Depressed mood | 15 | 3 |
|
|
|
||
| Other | 10 | 3 |
|
|
|||
| Bladder problems | 8 | 5 |
|
|
|
|
|
| Pain | 8 | 4 |
|
|
|
||
| Fibromyalgia | 7 | 3 |
|
|
|
||
| Anxious mood | 4 | 0 |
See all 55 patients currently taking Imipramine
Mouse over the table for more information
Commonly reported side effects, conditions, and hospitalizations associated with Imipramine
| Dry mouth (xerostomia) | 8 | |
|---|---|---|
| Difficulty with orgasm | 3 | |
| Constipation | 2 | |
| Weight gain | 1 | |
| Blurry vision | 1 | |
| Dry eyes | 1 | |
| See all 24 reported side effects ▼ | ||
Frequently reported dosages based on patients currently taking Imipramine. See all 15 dosages ►
| Reason | # Patients | Percentage of patients | |
|---|---|---|---|
| Did not seem to work | 12 | ||
| Side effects too severe | 9 | ||
| Doctor's advice | 5 | ||
| Other | 3 | ||
| Expense | 2 | ||
| Course of treatment ended | 2 | ||
| Personal research | 1 | ||
| Change in health plan coverage | 1 |
Adherence
Taking treatment as prescribed
Adherence of Imipramine
Always |
25 | 96% |
|
|---|---|---|---|
Usually |
1 | 4% |
|
Sometimes |
0 | 0% |
|
Never |
0 | 0% |
|
Burden
Difficulty being on treatment
Burden of Imipramine
Very |
2 | 8% |
|
|---|---|---|---|
Somewhat |
1 | 4% |
|
A little |
4 | 15% |
|
Not at all |
19 | 73% |
|
Cost
Paid out of pocket
Cost of Imipramine
$200+ |
0 | 0% |
|
|---|---|---|---|
$100-199 |
0 | 0% |
|
$50-99 |
0 | 0% |
|
$25-49 |
2 | 12% |
|
< $25 |
15 | 88% |
|
See more information, including instructions, precautions, side effects, and interactions.
Report created on February 10, 2012.